Splenic T2 signal intensity loss on MRI is associated with disease burden in multiple myeloma
Christian Neelsen(German Cancer Research Center), Niels Weinhold(German Cancer Research Center), Felix T. Kurz(German Cancer Research Center), Christos Sachpekidis(Democritus University of Thrace), Martin Grözinger(German Cancer Research Center), Marc S. Raab(Unknown), Lukas John(University of Hohenheim), Daniel Paech(Mass General Brigham), Peter Neher(German Cancer Research Center), Markus Wennmann(German Cancer Research Center), Elias Mai(Heidelberg University), H Schlemmer(German Cancer Research Center), Sandra Sauer(Heidelberg University), Antonia Dimitrakopoulou‐Strauss(German Cancer Research Center)
Cited by 2
Related Papers
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
|Blood|2018|492
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
|Leukemia|2018|452
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
|Nature Communications|2017|418
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
|Blood|2016|253
Review and consensus recommendations on clinical <scp>APT</scp>‐weighted imaging approaches at <scp>3T</scp>: Application to brain tumors
|Magnetic Resonance in Medicine|2022|236